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lematic. There is no single ICD-9 code to identify FN; therefore an algorithm must be 
created to identify FN patients. Previously published algorithms are generally com-
prised of 3 main codes: (1) neutropenia (primary designation (ICD-9 code 288.0)) (2) 
fever (ICD-9 780.6) (3) infection. However, the primary designation of neutropenia 
is only used if there is no clear source of infection. Additionally, infection in the 
neutropenic cancer patient can often be difﬁcult to conﬁrm due to the lack of neutro-
phils and typical clinical symptoms and signs; the febrile response may also be blunted. 
Therefore, the FN algorithm may use neutropenia alone, likely identifying patients 
with neutropenia alone in addition to those with FN. In a study utilizing claims data, 
FN was deﬁned as primary or secondary diagnosis of neutropenia or infection during 
the ﬁrst chemotherapy course; 41% of cancer patient newly initiating chemotherapy 
were classiﬁed as having FN. When the FN deﬁnition was narrowed to primary or 
secondary diagnosis with neutropenia and either 1) fever or 2) infection 4.5% were 
classiﬁed as having FN; when the deﬁnition was broadened to diagnosis with neutro-
penia or fever or infection or a procedure code for infection treatment 64.7% were 
classiﬁed as having FN. There is a strong need to validate the coding associated with 
submitting medical claims for the treatment of FN in cancer patients receiving che-
motherapy in real-world practice in order to utilize claims data to investigate FN.
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OBJECTIVES: We introduce a method whereby the continuous enrollment require-
ment can be removed to increase the sample size and correct for incomplete informa-
tion with an advanced statistical technique. METHODS: The inverse probability 
weighted least squares model is used to estimate the outcomes from a sample that 
does not require continuous enrollment in the inclusion criteria. This method involves 
two steps: probabilities are estimated using a non-parametric approach, and standard 
errors of the outcomes regression are adjusted for the ﬁrst step estimation. RESULTS: 
To demonstrate the technique, we used U.S. claims data. Patients with incidents of 
cases of lung cancer were used. A total of 236 patients were identiﬁed without the 
continuous enrollment requirement of one year after diagnosis. With the continuous 
enrolment requirement, our sample size would be 87. Incomplete cases were more 
likely to have surgery and higher rates of comorbidities. R-squared increased 25% 
with the inverse probability weighted technique. Standard errors decreased with 35% 
and therefore improved the precision of our estimators. CONCLUSIONS: The con-
tinuous enrollment requirement does not have to be applied for pharmacoeconomical 
studies. Results might be biased if there are substantial differences between complete 
and incomplete observations. Even though there are no differences, removing this 
requirement increases the sample size and provides efﬁcient estimators, especially in 
rare events.
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BACKGROUND: Hand-foot syndrome or Hand-Foot skin reaction is a common 
adverse effect of certain chemotherapy agents, such as capecitabine or pegylated 
doxorubicin, where it is estimated to occur in 50% of cases. OBJECTIVES: The aim 
of this study is to develop and validate a hand-foot syndrome-speciﬁc quality of life 
scale in order to be able to measure the impact of the condition on patients and 
secondly to be able to assess the value of certain speciﬁc treatments in this indication 
METHODS: The questionnaire was developed after conducting a series of structured 
interviews with patients with forms of hand-foot syndrome of varying severity, which 
yielded a detailed and rigorous collection of verbatim transcripts. The Pilot-Testing 
are realised. RESULTS: Thirty-one items were identiﬁed, and 14 items were selected 
as being relevant and non-overlapping after initial evaluation. The ﬁrst question in 
the HFS14 addresses which member is affected (hand, foot or both). The second 
question addresses the pain with three possible responses (very, moderately or not 
painful). The 14 items can be organised in 2 modules: the ﬁrst module more speciﬁcally 
assesses the handicap generated by involvement of the “feet” and the second assesses 
the handicap generated by involvement of the “hands”. CONCLUSIONS: The hand-
foot syndrome-speciﬁc HFS14 scale is easy to use and meets the requirements of a 
quality of life scale. This scale now needs to be tested in longitudinal studies (for 
example in clinical trials) to conﬁrm its ability to measure a change in status.
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The FDA has advocated the PRO Draft Guidance released in 2006 as the main vehicle 
for evaluating PRO and HRQOL claims in oncology product approvals. Additionally, 
FDA-afﬁliated researchers have identiﬁed factors inhibiting acceptance of HRQOL-
based claims for oncology product labels, including: trial design, missing data, multi-
plicity, and inconsistent ﬁndings of HRQOL data. The views of the FDA on PRO and 
HRQOL claims are extensive per its own guidance, which puts forth detailed, restric-
tive requirements on use. These matters clarify why the FDA has not yet allowed the 
utilization of PRO or HRQOL data as primary evidence to support an oncology 
product approval. In contrast, the EMEA since its establishment in 1995 has con-
ducted authorizations without an explicitly deﬁned approach for evaluating HRQOL 
and other PRO data. Further, a reﬂective paper released in 2005 offered only broad 
recommendations on HRQOL labeling claims. As a result, the importance of HRQOL 
or other PRO data in the review process is based more broadly on its relevance to a 
given drug and overall assessment of the study in the eyes of the reviewers. The varying 
approaches between the FDA and the EMEA partly stem from divergent underlying 
organizational characteristics. The FDA enforces laws regarding medical product 
quality. Alternatively, the EMEA serves as a coordinating body, leaving enforcement 
responsibility to member states. Consequently, the EMEA provides more generic 
advice, whereas the FDA insists on rigorous criteria for conceptual and study design 
issues surrounding PRO claims. Otherwise, the EMEA is more likely to accept use of 
well-established PRO and HRQOL measures, whereas the FDA is inclined to request 
new PRO measures that explicitly satisfy the agency’s most recent evaluative stan-
dards. Finally, the FDA places greater focus on symptom-based endpoints reﬂecting 
the direct consequences of treatment, whereas the EMEA is more willing to accept 
global HRQOL claims.
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OBJECTIVES: To describe the association between the three-year average glycosylated 
hemoglobin (A1C) and cardiovascular outcomes in adults with type 2 diabetes mellitus 
(T2DM). METHODS: In this nested case-control study, 245,346 adults (≥18 years) 
with T2DM were identiﬁed among members of Kaiser Permanente Southern Califor-
nia. Type 2 diabetic patients had at least two ICD-9 diagnosis codes for T2DM (250.
x0, 250.x2) and either A1C > 7.5% or prescriptions for hypoglycemic agents from 
2002–2007. Using hospital records and death certiﬁcates, cases were deﬁned as 
patients with a nonfatal MI, nonfatal stroke, or death due to cardiovascular (CV) 
causes (MI, stroke, heart failure, arrhythmia, sudden cardiac death) in the period 
2005–2007. Four controls from the T2DM pool were matched to each case based on 
age, sex and index date (date of the case deﬁning event). A conditional logistic regres-
sion model was used to estimate the odds-ratio (OR) of cardiovascular events compar-
ing patients with an average A1C ≤ 6 % and those with average A1C > 8% to patients 
with average A1C between 6–8%, considered ‘near A1C target’. A1C categories were 
assigned to each patient based on average A1C over the three years prior to the index 
date. RESULTS: A total of 44,628 controls were matched to 11,157 cases. After 
adjusting for CV related medications, comorbidities, and other confounders, patients 
with an average A1C ≤6% were 50% more likely to experience a CV event than the 
‘near A1C target’ T2DM patients (OR = 1.50, 95% CI 1.33–1.69, p < 0.0001). 
Patients with an average A1C > 8% experienced a 14% increase in odds of a CV event 
(OR = 1.14, 95% CI 1.03–1.26, p = 0.01). CONCLUSIONS: Compared to those with 
mean A1C levels between 6–8%, patients with T2DM who achieved mean A1C levels 
of ≤6% or failed to decrease their A1C below 8% over a 3-year period are at increased 
risk for cardiovascular events.
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OBJECTIVES: To assess the impact of oral antidiabetics agents on weight change in 
Type 2 Diabetes Mellitus (T2DM) patients age 65 years and older. METHODS: An 
electronic medical record, General Electric Centricity research database, containing 
the ambulatory health records of US patients was used to conduct a historical cohort 
study of the T2DM elderly patients identiﬁed by ICD-9 codes, OAD prescription or 
both. Six months of continuous OAD monotherapy activity was required, and study 
period included 395 days pre/210 days post from the index date. Two BMI/weight 
readings were mandated, at baseline, and follow up. Data were analyzed using 
ANOVA with Tukey test to correct for multiple comparisons. RESULTS: A total of 
2720 patients with a primary diagnosis of T2DM were included in the study. The 
overall mean age was 72.7 years. Statistical signiﬁcant differences between users of 
different OADs at baseline were found for diastolic blood pressure (p = 0.0009), and 
age (p < 0.001) The most prescribed OAD medications were metformin (58.9%), 
glipizide (14.52%) and glimepiride (7.76%).The overall mean change in A1C level 
was −0.92 (p < 0.001) units and statistically signiﬁcant differences were found when 
compared Metformin/Glipizide (mean difference 0.51320, 95% CI 0.06411–0.96230). 
The overall mean baseline BMI among all of the OAD groups was 29.08 kg/m². 
Signiﬁcant differences in BMI units change were found for meglitinide users, (-1.27), 
metformin users (-1.06), and the sulfonylureas (-0.14). An average of 3.97 lb weight 
loss for all of the OAD groups was found. Major weight loss was found in the Met-
formin group (-6.41lb), and the Sulfonylureas group reported the least weight loss 
(-0.89lb). CONCLUSIONS: An association was found between the OAD use and 
